Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBT: 2020-2025

Historic EBT for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.

  • Oncology Institute's EBT fell 242.66% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.4 million, marking a year-over-year increase of 586.54%. This contributed to the annual value of -$64.7 million for FY2024, which is 2219.03% up from last year.
  • As of Q3 2025, Oncology Institute's EBT stood at -$16.5 million, which was down 242.66% from -$17.1 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's EBT ranged from a high of $19.5 million in Q1 2022 and a low of -$30.0 million during Q1 2023
  • For the 5-year period, Oncology Institute's EBT averaged around -$11.2 million, with its median value being -$15.5 million (2024).
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 260205.66% in 2022, then plummeted by 54062.27% in 2023.
  • Oncology Institute's EBT (Quarter) stood at -$12.6 million in 2021, then grew by 9.9% to -$11.4 million in 2022, then plummeted by 67.65% to -$19.1 million in 2023, then soared by 30.87% to -$13.2 million in 2024, then dropped by 25.2% to -$16.5 million in 2025.
  • Its EBT was -$16.5 million in Q3 2025, compared to -$17.1 million in Q2 2025 and -$19.6 million in Q1 2025.